Debates of Jan. 30th, 2023

(Return tabled)

Question No.1093—

[Eric Melillo, Conservative, Kenora, ON]

With regard to the Canada Revenue Agency: what is the total number of employees or full-time equivalents in each division and section of the agency (human resources, administration, corporate tax processing, etc.), broken down by year, since 2016?

(Return tabled)

Question No.1094—

[Rick Perkins, Conservative, South Shore—St. Margarets, NS]

With regard to the Ship Source Oil Pollution Fund (SSOPF): what are the details of all claims that were made through the fund since November 4, 2015, including, for each, (i) the amount, (ii) the date, (iii) the vessel impacted, (iv) the amount recovered to date, (v) the type of vessel, (vi) the location of the incident, (vii) the nation where the vessel was registered, (viii) whether it was a ministerial or departmental order?

(Return tabled)

Question No.1096—

[Rick Perkins, Conservative, South Shore—St. Margarets, NS]

With regard to Innovation, Science and Economic Development Canada: what was the total number of employees or full-time equivalents at the department, broken down by sector and agency, branch within the department, position level, type of job, for each fiscal year, since 2015-16?

(Return tabled)

Question No.1099—

[Rob Morrison, Conservative, Kootenay—Columbia, BC]

With regard to Arctic and offshore patrol ships (AOPS): (a) what were the total expenditures related to non-warranty repair work for AOPS, broken down by ship and by year since they were launched; and (b) what are the details of the non-warranty repair work, including, for each, the (i) date, (ii) ship, (iii) cost, (iv) description of the repair work?

(Return tabled)

Question No.1101—

[Earl Dreeshen, Conservative, Red Deer—Mountain View, AB]

With regard to government purchases of personal protective equipment (PPE) abroad using cash, including those made through a third party or intermediary, since January 1, 2020: what are the details of all cash purchases, including, for each, the (i) date, (ii) currency used, (iii) amount, in Canadian dollars and cash currency used to make the purchase, (iv) reason cash was used, (v) vendor, (vi) description of PPE purchased, including volume, (vii) name of third party of intermediary used, if applicable?

(Return tabled)

Question No.1102—

[Earl Dreeshen, Conservative, Red Deer—Mountain View, AB]

With regard to Governor in Council (GIC) appointments: (a) what is the total number of existing positions, including those filled and unfilled, broken down by year, since 2015; (b) what is the breakdown of (a) by portfolio; (c) what specific GIC positions have been added since November 4, 2015, and how many of each position have been added, broken down by year; and (d) what GIC positions have been eliminated since November 4, 2015, broken down by year?

(Return tabled)

Question No.1103—

[Scott Reid, Conservative, Lanark—Frontenac—Kingston, ON]

With regard to Automated External Defibrillators (AEDs): (a) since June 20, 2022, have any meetings, communications, briefings, or other informational materials pertaining to AEDs been requested, formally or informally, by the Minister of Public Safety, the office of the Minister of Public Safety, the office of the Deputy Minister of Public Safety, or the office of the Commissioner of the RCMP; (b) for each instance in (a), what was the (i) date the request was made, (ii) recipient or office to which the request was made, (iii) nature and details of the request, (iv) result of the request; (c) since June 20, 2022, have any briefing or informational materials pertaining to AEDs been provided to the Minister of Public Safety, the office of the Minister of Public Safety, the office of the Deputy Minister of Public Safety, or the office of the Commissioner of the RCMP; (d) for each instance in (c), what was the (i) date the material was provided, (ii) recipient or office to which the material was provided, (iii) topic of material provided; (e) since June 20, 2022, has the Minister of Public Safety issued any ministerial instructions, directives, or analogous decisions with regard to AEDs?

(Return tabled)

Question No.1104—

[Scott Reid, Conservative, Lanark—Frontenac—Kingston, ON]

With regard to the report entitled "Minister of National Defence Advisory Panel on Systemic Racism and Discrimination with a focus on Anti-Indigenous and Anti-Black Racism, LGBTQ2+ Prejudice, Gender Bias, and White Supremacy Final Report": (a) have any meetings, communications, briefings, or other informational materials with regard to chaplaincy, or section 6 of Part III entitled “Re-Defining Chaplaincy” been requested, formally or informally, by the Minister of National Defence, the office of the Minister of National Defence, the office of the Deputy Minister of National Defence, or the office of the Chief of the Defence Staff; (b) for each instance in (a), what was the (i) date the request was made, (ii) recipient or office to which the request was made, (iii) nature and details of the request, (iv) result of the request; (c) have any briefing or informational materials with regard to chaplaincy, or section 6 of Part III entitled “Re-Defining Chaplaincy” been provided to the Minister of National Defence, the office of the Minister of National Defence, the office of the Deputy Minister of National Defence, or the office of the Chief of the Defence Staff; (d) for each instance in (c), what was the (i) date the material was provided, (ii) recipient or office to which the material was provided, (iii) topic of the material provided; (e) since January 2022, has the Minister of National Defence issued any ministerial instructions, directives, or analogous decisions with regard to chaplaincy, or section 6 of Part III entitled “Re-Defining Chaplaincy”; and (f) have any actions been taken with regard to the recommendations on page 43 of the report, and, if so, what are the details of those actions?

(Return tabled)

Question No.1105—

[Scott Reid, Conservative, Lanark—Frontenac—Kingston, ON]

With regard to Correctional Service Canada’s (CSC) Chaplaincy Program: (a) since November 2015, have any meetings, communications, briefings, or other informational materials been requested, formally or informally by the Minister of Public Safety, the office of the Minister of Public Safety, the office of the Deputy Minister of Public Safety, or the office of the Commissioner of the Correctional Service of Canada; (b) for each instance in (a), what was the (i) date the request was made, (ii) recipient or office to which the request was made, (iii) nature and details of the request, (iv) result of the request; (c) since November 2015, have any briefing or informational materials been provided to the Minister of Public Safety, the office of the Minister of Public Safety, the office of the Deputy Minister of Public Safety, or the office of the Commissioner of the Correctional Service of Canada; (d) for each instance in (c), what was the (i) date the material was provided, (ii) recipient or office to which the material was provided, (iii) topic of the material provided; (e) since November 2015, has the Minister of Public Safety issued any ministerial instructions, directives, or analogous decisions with regard to CSC’s Chaplaincy Program; (f) how many chaplains are presently members of CSC’s Chaplaincy Program, broken down by faith, spiritual, or philosophical tradition; (g) how many members of CSC’s Chaplaincy Program are assigned to or responsible for each of CSC’s institutions or custodial facilities, broken down by faith, spiritual, or philosophical tradition; and (h) since November 2015, what actions have been taken to address the proportionate shortage of non-Christian members of CSC’s Chaplaincy Program and, if any, what are the details of those actions?

(Return tabled)

Question No.1106—

[Colin Carrie, Conservative, Oshawa, ON]

With regard to the clinical trials conducted on COVID-19 vaccine safety, specifically those pertaining to the widely distributed vaccines by Pfizer/BioNTech and Moderna that Health Canada reviewed: (a) were objections raised by the government when these vaccines were allowed to be given to the relatively healthy, unvaccinated trial participants mid-way into Phase 3 of the placebo-controlled clinical trials; (b) if no action was taken in relation to (a), why not; (c) of the safety data that could be analyzed, showing level-1 evidence of vaccine-induced harm (e.g. a risk increase in severe adverse events, more death, and after dissolution of the control group, more deaths in the experimental group), how were they used, if at all, when performing risk-benefit analyses; and (d) what specific information was used by the government to arrive at their position that there was more benefit to administering the COVID-19 vaccines to relatively healthy Canadians than risk?

(Return tabled)

Question No.1107—

[Colin Carrie, Conservative, Oshawa, ON]

With regard to the clinical trials conducted on COVID-19 vaccine effectiveness, specifically those pertaining to the widely distributed vaccines by Pfizer/BioNTech and Moderna that Health Canada reviewed, vaccine mandates, and vaccination campaigns: (a) how many trial participants contracted COVID-19, broken down by participants in the experimental and control groups, versus the total number of participants; (b) why was the information in (a), necessary for ascertaining the absolute risk reduction of acquiring COVID-19 following vaccination, not communicated to the general public to enable a more realistic assessment of health risks in support of informed consent; (c) did any trial protocol deviations occur in trial participants who contracted COVID-19; (d) was the government aware that the clinical trials did not test the ability of the vaccines to stop viral transmission before implementing the federal vaccination policy for government employees, whose stated objectives include the protection of these employees as well as their colleagues and clients from COVID-19; (e) if the answer to (d) is affirmative, what was the justification to mandate relatively healthy government employees to get vaccinated against SARS-CoV-2; (f) who made the decision to implement the policy in (d); and (g) how does the government justify its continued campaigns to encourage vaccination in relatively healthy Canadians, starting as young as 6 months?

(Return tabled)

Question No.1108—

[Colin Carrie, Conservative, Oshawa, ON]

With regard to Health Canada's (HC) approval of the Pfizer COVID-19 mRNA vaccine (BNT162b2): (a) was HC aware that the World Health Organization's internationally accepted guidelines for vaccine evaluation, published in 2005 and 2014, are only applicable to traditional vaccines that contain immunogenic substances and adjuvants, and, if not, why not; (b) if the answer to (a) is affirmative, why did HC not require the use of a guidance document applicable to non-traditional COVID-19 mRNA vaccines that are based instead on gene therapy, such as BNT162b2; (c) did the non-clinical pharmacokinetic studies, which also evaluated the biodistribution of the BNT162b2 (V9) lipid nano-particle (LNP) formulation, reported by Pfizer, show extensive off-target biodistribution to major organs in rodents; (d) if the answer to (c) is affirmative, did HC consider the non-clinical biodistribution data to be a major safety concern, and, if not, why not; (e) were clinical pharmacokinetic studies on the biodistribution of the vaccine-encoded spike protein included in the regulatory submission, and, if not, why not; (f) were clinical studies on appropriate biomarkers (e.g. troponin-1 as an indicator for heart damage, C-reactive protein for inflammation) associated with possible vaccine adverse effects related to spike protein in the blood circulation, included in the regulatory submission, and, if not, why not; (g) were clinical studies on the variability of vaccine-generated spike protein concentration between different vaccine recipients for different lots of the COVID-19 mRNA vaccines administered included in the regulatory submission, and, if not, why not; (h) did HC request that relevant genotoxicity and carcinogenicity studies on the vaccine-generated spike protein, as the active component, be included in the regulatory submission, and, if not, why not; (i) why did HC find as acceptable non-clinical studies of vaccine safety using Wistar Han rats; (j) why did HC find as acceptable toxicology studies on the vaccine-generated spike protein that did not also use a non-rodent species; (k) why did HC find as acceptable toxicology studies that did not use a relevant rodent species, such as the Chinese golden hamster, to examine toxic effects of the vaccine-generated spike protein; (l) why did HC not request toxicology studies using Chinese golden hamsters to examine the distribution of vaccine-generated spike protein in the specific tissues of both the mother and the pups to gather information as to whether BNT162b2 is suitable to administer to pregnant women and mothers who are breastfeeding, for more trustworthy clinical data; (m) was HC aware that Table 1 in the Module 5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports, submitted by Pfizer, states that there were 1,223 deaths over a 3-month period, from December 1, 2020 to February 28, 2021; (n) if the answer to (m) is affirmative, why did HC not recommend that COVID-19 mRNA vaccines be immediately taken off the market on the basis of the high mortality rate following drug administration; (o) has HC investigated the flaws in the documentation of Pfizer's regulated study, as shown in Table 1 of the aforementioned report, which classified the case outcomes of 9,400 people as "unknown," and which indicated that the age of 6,876 cases could not be determined, and, if not, why not; (p) how does HC justify its position that there is no special COVID-19 vaccine hazard for humans based on conventional studies of repeat dose toxicity, when not even immune-histochemistry staining for the vaccine-encoded spike protein was performed with any relevant species; and (q) how does HC view the real-world effectiveness of the COVID-19 mRNA vaccines in reducing viral transmission, when considering peer-reviewed studies that document similar peak loads of viable SARS-CoV-2 virus in the upper airway of fully vaccinated infected individuals and unvaccinated infected individuals, as well as reports of vaccine-induced immune suppression, indicated by reduced production of viral N-protein antibodies following breakthrough infection?

(Return tabled)